开始
JetEquities

Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxi

做多
Atossa Therapeutics, Inc. (NASDAQ:ATOS)  
JetEquities  
NASDAQ:ATOS   Atossa Therapeutics, Inc.
Beyond Technical Analysis
3
0
beyondta
ATOS: Atossa Genetics Inc.
2019-12-19 08:30:10
Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women
免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。